Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

RA drugs under the microscope: which one keeps you stronger?

NCT ID NCT07182630

Knowledge-focused Sponsor: Firat University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how two types of rheumatoid arthritis (RA) drugs—anti-TNF-α and non-TNF-α—affect patients' aerobic capacity, muscle strength, fatigue, and heart disease risk factors. Researchers will measure oxygen use during exercise, muscle strength, and disease activity in 40 adults aged 18-65 who have been on these drugs for 1-3 years. The goal is to understand which treatment better supports physical fitness and overall health in RA patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anti-TNF-α and non-TNF-α drugs
What this could lead to
If successful, this study could help doctors choose RA treatments that better preserve patients' physical fitness and reduce heart disease risk.
What could go wrong
This is a small, early-stage observational study with only 40 participants, so results may not apply to all RA patients. It measures changes but does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include 40 patients aged 18-65 who are being followed up at the Department of Rheumatology at Fırat University Hospital and who have been diagnosed with RA according to the 2010 RA criteria of the American College of Rheumatology (ACR).

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with RA according to the 2010 American College of Rheumatology (ACR-2010) criteria * Be between 18 and 65 years of age * Be literate * Have been using one of the anti-TNF-α or non-TNF-α drugs for a period of 1-3 years Exclusion Criteria: * Being pregnant or having a diagnosis of malignancy * Having a dysfunction that would limit physical activity (cycling for aerobic capacity assessment), such as severe neurological involvement, immobility, or incooperation * Having a regular exercise habit (reporting a habit of exercising 3 or more days per week) * Having another chronic disease * Having cardiac symptoms according to the New York Heart Association * Having mental problems that prevent participation in assessments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fırat University

    Elâzığ, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.